Objectives: To evaluate the cost-effectiveness of first-line treatment of Overactive Bladder (OAB) with fesoterodine relative to mirabegron, from the Spanish National Health System (NHS) perspective.
Methods: A decision tree model was developed to represent a typical clinical process of 52-week of treatment for an OAB patient with urge urinary incontinence (UUI) initiating first-line therapy with fesoterodine 4mg, including optional titration to 8mg, vs.mirabegron 50mg. Efficacy data were obtained from a Bayesian indirect treatment meta-analysis. Patients with UUI of less than one episode/day were defined as treatment responder and persistence was assessed at weeks 4, 12 and 24. At week 12, non-responders discontinued treatment permanently. Quality-adjusted life years (QALYs) were calculated based on time spent in responder and non-responder states. OAB-related drug and medical care costs including physician visits, laboratory tests, incontinence pads, and comorbidities (fracture, skin infection, urinary tract infections and depression) were modeled and expressed in €2015.
Results: At week 52, the percentage of responders was 20.8% for patients starting on fesoterodine 4mg who optionally titrated to 8mg and 19.4% for patients treated with mirabegron. QALYs were slightly higher with fesoterodine than mirabegron (0.7703vs. 0.7668, difference=0.0035). Fesoterodine treatment also had slightly higher total costs than mirabegron (3,296€vs. 3,217, difference=79€), resulting in a cost of 22,523/QALY€ gained for fesoterodine versus mirabegron. Probabilistic sensitivity analysis confirmed the slight advantage of fesoterodine with a 61.1% probability of being cost-effective at the 30,000€ willingness-to-pay for 1QALY threshold.
Conclusions: Given the relatively small 1-year cost difference between the two treatments, fesoterodine can be considered a cost-effective option relative to mirabegron for the first-line management of OAB with UUI in Spain.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.acuro.2015.11.012 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Drug-induced urinary retention: a real-world pharmacovigilance study using FDA and Canada vigilance databases.
Front Pharmacol
January 2025
Department of Urology, The First Hospital of Jilin University, Changchun, China.
Background: Urinary retention (UR) is a clinical condition where patients cannot fully empty their bladder. Although numerous drugs are associated with UR, comprehensive and reliable studies identifying drugs that induce UR are scarce.
Methods: This study leveraged data from the FDA Adverse Event Reporting System (FAERS) and the Canadian Vigilance Adverse Reaction (CVAR) database to explore adverse events (AEs) related to UR from 2004 to Q1 2024.
Trends in Medicare Coverage of Overactive Bladder Medications in the United States.
Urogynecology (Phila)
December 2024
From the Urogynecology and Reconstructive Pelvic Surgery, MedStar Washington Hospital Center/Georgetown University, Washington, DC.
Importance: Strong evidence demonstrates long-term cognitive decline associated with anticholinergics. While prevalent among older populations, medical management of overactive bladder (OAB) is dictated by insurance coverage rather than medical provider and patient preferences.
Objective: The aim of this study was to assess Medicare insurance plan coverage for select OAB medications and evaluate coverage of preferred medications to medications with a greater risk of cognitive dysfunction.
Risk of dementia associated with anticholinergic drugs for overactive bladder in adults aged ≥55 years: nested case-control study.
BMJ Med
November 2024
Centre for Academic Primary Care, School of Medicine, University of Nottingham, Nottingham, UK.
Article Synopsis
- The study aimed to assess the risk of developing dementia associated with different anticholinergic drugs prescribed for overactive bladder among older adults in England.
- Utilizing data from the Clinical Practice Research Datalink, researchers conducted a nested case-control study involving over 170,000 patients diagnosed with dementia, alongside matched controls without dementia.
- Results indicated a slightly elevated risk of dementia (odds ratio of 1.18) linked to anticholinergic drug use, with a higher risk observed in men compared to women.
Disproportionality analysis of drug-induced dry mouth using data from the United States food and drug administration adverse event reporting system database.
Heliyon
October 2024
Department of Oral and Maxillofacial Surgery, The Affiliated Huaian No.1 People's Hospital of Nanjing Medical University, Huaian, 223300, Jiangsu Province, China.
Article Synopsis
- The study investigates the link between various medications and drug-induced dry mouth, which impacts patients' quality of life.
- Data was collected from the FDA's Adverse Event Reporting System from 2004 to 2024, analyzing 75,899 reports of dry mouth.
- Findings indicated tiotropium bromide monohydrate was most commonly reported for causing dry mouth, while darifenacin had the highest risk; many implicated drugs lacked proper labeling for this side effect.
An Investigational Study on the Role of , and s Genetic Variation on Fesoterodine Pharmacokinetics in Young Healthy Volunteers.
Pharmaceuticals (Basel)
September 2024
Clinical Pharmacology Department, Hospital Universitario de La Princesa, Faculty of Medicine, Universidad Autónoma de Madrid (UAM), Instituto de Investigación Sanitaria La Princesa (IP), 28006 Madrid, Spain.
Fesoterodine is one of the most widely used antimuscarinic drugs to treat an overactive bladder. Fesoterodine is extensively hydrolyzed by esterases to 5-hydroxymethyl tolterodine (5-HMT), the major active metabolite. CYP2D6 and CYP3A4 mainly metabolize 5-HMT and are, therefore, the primary pharmacogenetic candidate biomarkers.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!